Press releases

Press release 2015/12/21

Medivir announces that development of the HCV nucleotide polymerase inhibitor AL-704 was terminated by Janssen

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the development of AL-704 (also known as JNJ-54257099) has been...

Read more

Press release 2015/11/20

MEDIVIR AB – INTERIM REPORT, THIRD QUARTER 2015

Financial summary Third quarter 2015 (2014) Net turnover totalled SEK 111.5 million (617.8 m), of which SEK 69.0 million (516.4 m)...

Read more

Press release 2015/11/17

Medivir terminates the ADAM8 inhibitor project for pancreatic cancer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that it will terminate its ADAM8 inhibitor project for pancreatic cancer....

Read more

Press release 2015/10/16

Medivir announces that Janssen has started a phase IIa study to evaluate the effect of simeprevir in combination with odalasvir and AL-335

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies (Janssen),...

Read more

Press release 2015/10/13

OLYSIO® sales during the third quarter 2015

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the global third quarter net sales of OLYSIO® (simeprevir) amounted to...

Read more

Press release 2015/09/16

Medivir to merge Research and Development and implement changes within the management group

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that, as the next step in the company's optimisation process, its...

Read more

Press release 2015/08/20

MEDIVIR AB – INTERIM REPORT, SECOND QUARTER 2015

Financial summary Second quarter 2015 (2014) Net turnover totalled SEK 245.8 million (564.0 m), of which SEK 165.6 million (500.7 m)...

Read more

Press release 2015/08/03

Medivir announces that Janssen has started a phase I study to evaluate the effect of simeprevir and odalasvir on AL-335 pharmacokinetics

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies (Janssen)...

Read more

Press release 2015/07/29

Medivir announces start of a phase I clinical trial of the nucleotide polymerase inhibitor AL-704 for treatment of hepatitis C

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces the start of a phase I clinical trial with AL-704, also...

Read more

Press release 2015/07/24

Medivir announces that Janssen submitted supplemental New Drug Application to U.S. FDA for OLYSIO® (simeprevir) in combination with sofosbuvir

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that Janssen Products, LP (Janssen ), has submitted a supplemental New...

Read more

Press release 2015/07/14

OLYSIO® sales during the second quarter 2015

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the global second quarter net sales of OLYSIO® (simeprevir) amounted to...

Read more

Press release 2015/06/30

Medivir announces the first cancer project derived from its in-house nucleotide platform

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces a new discovery project for a cancer indication, a liver targeted...

Read more